WILSON KAREN J — SEC insider filings
SEC reporting owner CIK 1267490. 16 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 16 filings on record, filed 2020-08-27 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 2 filings — 30,100 shares, $54,750 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: purchase of 10,000 shares @ $1.93 ($19,300) in Serina Therapeutics, Inc., filed 2026-05-26.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | Director | 5 | 4 legs · 30,100 sh · $54,750 | — | 3 |
| Elicio Therapeutics, Inc. (ELTX) | Director | 7 | — | — | 8 |
| LAVA Therapeutics NV (LVTX) | Director | 2 | — | — | 3 |
| Vaxart, Inc. (VXRT) | Director | 2 | — | — | 2 |
Insider filings — WILSON KAREN J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 21,750 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 15,250 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Serina Therapeutics, Inc. (SER) | Purchase (P): 5,100 @ $1.75 · Purchase (P): 5,000 @ $1.77 | EDGAR |
| 2026-05-26 | 4 | Serina Therapeutics, Inc. (SER) | Purchase (P): 10,000 @ $1.77 · Purchase (P): 10,000 @ $1.93 | EDGAR |
| 2025-11-17 | 4 | LAVA Therapeutics NV (LVTX) | Disposition to issuer (D): 10,000 · Disposition to issuer (D): 33,390 (derivative) @ $0 | EDGAR |
| 2025-11-10 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 7,900 (derivative) @ $0 | EDGAR |
| 2025-02-18 | 4 | LAVA Therapeutics NV (LVTX) | Grant/award (A): 33,390 (derivative) @ $0 | EDGAR |
| 2025-01-15 | 4 | Serina Therapeutics, Inc. (SER) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-11-25 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | Elicio Therapeutics, Inc. (ELTX) | Grant/award (A): 4,100 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Vaxart, Inc. (VXRT) | Grant/award (A): 15,097 (derivative) @ $0 | EDGAR |
| 2021-03-10 | 4 | Angion Biomedica Corp. (ANGN) | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2021-02-11 | 4 | Angion Biomedica Corp. (ANGN) | Conversion (C): 18,718 @ $11.57 · Conversion (C) @ $0 | EDGAR |
| 2020-08-27 | 4 | Vaxart, Inc. (VXRT) | Grant/award (A): 65,700 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-08-26 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1267490 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs